Coronary stent SYNERGY MEGATRON™

platinium-chromiumpolymerdrug eluting

Product overview
The SYNERGY MEGATRON™ Everolimus‑Eluting Platinum Chromium Coronary Stent System is a bioabsorbable‑polymer drug‑eluting stent engineered for large proximal coronary vessels. The design emphasizes axial and radial strength, wide overexpansion capability, enhanced radiographic visibility and uniform lesion scaffolding. The device features synchronous drug elution and polymer absorption via an abluminal bioabsorbable polymer.

Key features

• High axial and radial strength to support stent integrity and vessel patency
• Wide overexpansion range — nominal models expandable from 3.5 mm up to 6.0 mm to treat tapered vessels
• Platinum‑Chromium (PtCr) alloy for maximum radiographic visibility
• 12‑peak stent architecture to minimize tissue prolapse and support lumen gain
• Abluminal bioabsorbable polymer optimized for Everolimus delivery and synchronized absorption
• Indicated for use in STEMI and in selected high bleeding risk (HBR) patients

Best‑in‑Class Axial & Radial Strength
The stent geometry and material deliver improved axial strength for device integrity in complex interventions and enhanced radial strength to maintain vessel patency. Bench comparisons cited higher axial and radial strength versus comparators (bench test data on file).

Unmatched Overexpansion Range
The platform accommodates significant diameter mismatch by supporting overexpansion of up to 2.5 mm (for example, nominal 3.5 mm expandable to 6.0 mm), enabling treatment of tapered vessels.

Maximum Visibility
Platinum‑Chromium (PtCr) alloy enhances radiopacity to aid precise stent placement under fluoroscopy.

Uniform Lesion Scaffolding
The 12‑peak architecture is designed to reduce tissue prolapse and help maintain lumen diameter, maximizing lumen gain after deployment.

Indications and Clinical Evidence
Indicated for use as a coronary drug‑eluting stent system, including treatment of STEMI patients. The SYNERGY platform combines thin, rounded PtCr struts with optimized Everolimus delivery and a fast‑absorbing abluminal bioabsorbable polymer to support early healing.

CLEAR SYNERGY Stent Registry (selected results)
Evaluated SYNERGY in STEMI patients (n=733). Reported outcomes: 4.8% MACE (cardiovascular death, recurrent MI, or ischemia‑driven TVR), 0.8% TLR, 1.1% stent thrombosis (0.3% within 24 hours).

EVOLVE Short DAPT Trial (selected summary)
EVOLVE Short DAPT assessed safety of 3‑month DAPT in high bleeding risk subjects treated with the SYNERGY BP Stent (N≈1,396). Trial data support consideration of shortened DAPT in selected HBR patients when clinically appropriate.

Ordering information (selected)
Nominal diameters available: 3.50 mm, 4.00 mm, 4.50 mm, 5.00 mm. Lengths commonly offered: 8, 12, 16, 20, 24, 28, 32 mm. Overexpansion capability: up to 6.0 mm (supporting expansion from 3.5 mm to 6.0 mm). Specific catalog references are provided in the manufacturer's ordering table.

Notes / Bench data
Bench test data and referenced comparisons are on file with the manufacturer; bench results are not necessarily indicative of clinical performance.

Specifications / technical characteristics

• Commercial name: SYNERGY MEGATRON™
• Drug: Everolimus (drug‑eluting)
• Alloy: Platinum‑Chromium (PtCr)
• Polymer: Abluminal bioabsorbable polymer with synchronous drug elution and polymer absorption
• Strut / design: Thin, rounded PtCr struts; 12‑peak architecture for uniform lesion scaffolding
• Nominal diameters: 3.50 mm, 4.00 mm, 4.50 mm, 5.00 mm
• Overexpansion capability: up to 6.0 mm (supports expansion from 3.5 mm to 6.0 mm)
• Indications (selected): Coronary drug‑eluting stent system; indicated for treatment of STEMI patients; indicated for use in selected high bleeding risk patients
• Clinical highlights: CLEAR SYNERGY registry (STEMI, n=733) — MACE 4.8%; TLR 0.8%; ST 1.1%. EVOLVE Short DAPT trial evaluated shortened (3‑month) DAPT in HBR patients (N≈1,396).